|Application ||WB, IF, E|
|Other Accession||NP_001014446, 62244044|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||16954 Da|
|Application Notes||OCIAD2 antibody can be used for detection of OCIAD2 by Western blot at 0.5 - 1 µg/mL. Antibody can also be used for immunoflourescence starting at 20 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Reconstitution & Storage||OCIAD2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||OCIAD2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
OCIAD2 Antibody: OCIAD2 was identified by its sequence similarity with OCIAD1, and together OCIAD1 and OCIAD2 form the OCIA domain family. OCIAD2 mRNA was found to be expressed at higher levels in invasive adenocarcinoma mixed subtype with bronchioloalveolar carcinoma component (BAC) of the lung. Loss of OCIAD2 expression was significantly correlated with lymphatic invasion, blood vessel invasion, and lymph node metastasis, indicating that OCIAD2 may play a role in cell adhesion and prevention of cell migration. While the function of OCIAD2 is still unknown, its expression in adenocarcinoma with BAC component is significantly associated with a favorable prognosis and may serve as a marker for selecting tumors that are treatable by limited surgery.
Strausberg RL, Feingold EA, Grouse LH, et al. Mammalian gene collection program team. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl. Acad. Sci. USA2002; 99:16899-903.
Ishiyama T, Kano J, Anami Y, et al. OCIA domain containing 2 is highly expressed in adenocarcinoma mixed subtype with bronchioloalveolar carcinoma component and is associated with better prognosis. Cancer Sci.2006; 98:50-7.
If you have any additional inquiries please email technical services at email@example.com.